Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events.
OBJECTIVE
QT dispersion, measured as interlead variability of QT intervals in the surface electrocardiogram, has been demonstrated to provide an indirect measurement of the inhomogeneity of myocardial repolarization. The purpose of the present study was twofold: (1) to analyze the effect of amiodarone on QT dispersion measured in the 12-lead standard ECG, and (2) to examine the association between QT dispersion on amiodarone and subsequent arrhythmic events.


METHODS
To determine the effect of amiodarone on QT dispersion and its clinical significance for subsequent arrhythmic events, QT dispersion was measured in the 12-lead standard electrocardiogram (ECG) in 52 patients before and after administration of empiric amiodarone for ventricular tachyarrhythmias.


RESULTS
QT intervals increased from 401 +/- 44 ms before amiodarone to 442 +/- 53 ms after amiodarone therapy, and rate corrected QT intervals (QTc) increased from 452 +/- 43 ms to 477 +/- 37 ms, respectively (p < 0.01). QT dispersion, QTc dispersion, and adjusted QTc dispersion, which take account of the number of leads measured, were not significantly different before and after initiation of amiodarone therapy (58 +/- 24 ms vs. 61 +/- 26 ms, 68 +/- 29 vs. 66 +/- 26 ms, and 22 +/- 8 vs. 22 +/- 8 ms, respectively, p = NS). During 31 +/- 25 months follow-up after initiation of amiodarone therapy, arrhythmic events defined as sustained ventricular tachycardia, ventricular fibrillation, or sudden death occurred in 11 of 52 study patients (21%). QT dispersion, QTc dispersion, and adjusted QTc dispersion on amiodarone were not different between patients with and without arrhythmic events during follow-up (65 +/- 14 vs. 59 +/- 29 ms, 73 +/- 15 vs. 64 +/- 28 ms, and 25 +/- 6 vs. 21 +/- 8 ms, respectively, p = NS).


CONCLUSIONS
We conclude that (1) amiodarone increases QT intervals and QTc intervals during sinus rhythm but does not significantly change measures of QT dispersion; and (2) QT dispersion measured in the 12-lead standard ECG after initiation of amiodarone therapy does not appear to be a useful marker for subsequent arrhythmic events.
Grimm
W
W
Department of Cardiology, Hospital of the Philipps-University of Marburg, Germany.
Steder
U
U
Menz
V
V
Hoffmann
J
J
Maisch
B
B
D000638:Amiodarone / Q000008:administration & dosage / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016757:Death, Sudden, Cardiac; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume / Q000187:drug effects; D017180:Tachycardia, Ventricular / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000209:etiology / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone